A5084315678- Inhalation and Respiratory Drug Delivery
- Respiratory viral infections research
- Infection Control and Ventilation
- Asthma and respiratory diseases
- Monoclonal and Polyclonal Antibodies Research
- Protein purification and stability
- Influenza Virus Research Studies
University of Hong Kong
2021-2023
University College London
2023
HKU-Pasteur Research Pole
2022
Neutralising monoclonal antibody (mAb) is an important weapon in our arsenal for combating respiratory viral infections. However, the effectiveness of neutralising mAb has been impeded by rapid emergence mutant variants. Early administration broad-spectrum with improved delivery efficiency can potentially enhance efficacy and patient outcomes. WKS13 a humanised which was previously demonstrated to exhibit activity against SARS-CoV-2 In this study, dual targeting formulation strategy designed...
Abstract In response to the epidemic and pandemic threats caused by emerging respiratory viral infections, a safe efficient broad‐spectrum antiviral therapy at early onset of infection can significantly improve patients’ outcome. Inhaled dry powder is easy administer delivers agent directly primary site infection, thereby minimizing systemic side effects. Here, spray freeze drying (SFD) technique employed formulate tamibarotene, retinoid derivative with activity, as inhalable powder. The SFD...
Unpredictable outbreaks due to respiratory viral infections emphasize the need for new drug delivery strategies entire tract. As attack is not limited a specific anatomic region, antiviral therapy that targets both upper and lower tract would be most effective. This study aimed formulate tamibarotene, retinoid derivative previously reported display broad-spectrum activity against influenza severe acute syndrome coronavirus-2 (SARS-CoV-2), as novel dual particle size powder formulation nasal...